{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:34:22Z","timestamp":1792978462974,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,5,15]],"date-time":"2021-05-15T00:00:00Z","timestamp":1621036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,5,15]],"date-time":"2021-05-15T00:00:00Z","timestamp":1621036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi-Aventis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s40801-021-00250-x","type":"journal-article","created":{"date-parts":[[2021,5,15]],"date-time":"2021-05-15T17:02:36Z","timestamp":1621098156000},"page":"369-382","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Correlation of Objective Endpoints and Subjective Patient-Reported Outcomes in NAFLD Treatment with Essential Phospholipids: Real-World Data Based on Pooled Analysis of Observational Studies"],"prefix":"10.1007","volume":"8","author":[{"given":"Vladimir T.","family":"Ivashkin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina V.","family":"Maevskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena N.","family":"Shirokova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor V.","family":"Maev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey A.","family":"Samsonov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeniy I.","family":"Sas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liudmila K.","family":"Palgova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6488-7980","authenticated-orcid":false,"given":"Kirill","family":"Starostin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,15]]},"reference":[{"issue":"4","key":"250_CR1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/cld.81","volume":"1","author":"P Puri","year":"2012","unstructured":"Puri P, Sanyal AJ. Nonalcoholic fatty liver disease: definitions, risk factors, and workup. Clin Liver Dis (Hoboken). 2012;1(4):99\u2013103. https:\/\/doi.org\/10.1002\/cld.81.","journal-title":"Clin Liver Dis (Hoboken)."},{"issue":"1","key":"250_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73\u201384. https:\/\/doi.org\/10.1002\/hep.28431.","journal-title":"Hepatology"},{"issue":"6","key":"250_CR3","first-page":"31","volume":"25","author":"VT Ivashkin","year":"2015","unstructured":"Ivashkin VT, Drapkina OM, Mayev IV, Trukhmanov AS, Blinov DV, Palgova LK, et al. Prevalence of non-alcoholic fatty liver disease in out-patients of the Russian Federation: DIREG 2 study results. Russ J Gastroenterol Hepatol Coloproctol. 2015;25(6):31\u201341.","journal-title":"Russ J Gastroenterol Hepatol Coloproctol."},{"issue":"1","key":"250_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/TP.0000000000002484","volume":"103","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Marchesini G, Pinto-Cortez H, Petta S. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: implications for liver transplantation. Transplantation. 2019;103(1):22\u20137. https:\/\/doi.org\/10.1097\/TP.0000000000002484.","journal-title":"Transplantation"},{"issue":"1","key":"250_CR5","first-page":"20","volume":"11","author":"CI Andronescu","year":"2018","unstructured":"Andronescu CI, Purcarea MR, Babes PA. Nonalcoholic fatty liver disease: epidemiology, pathogenesis and therapeutic implications. J Med Life. 2018;11(1):20\u20133.","journal-title":"J Med Life."},{"issue":"4","key":"250_CR6","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","volume":"67","author":"M Romero-Gomez","year":"2017","unstructured":"Romero-Gomez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017;67(4):829\u201346. https:\/\/doi.org\/10.1016\/j.jhep.2017.05.016.","journal-title":"J Hepatol."},{"issue":"1 Suppl","key":"250_CR7","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","volume":"62","author":"CD Byrne","year":"2015","unstructured":"Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1 Suppl):S47-64. https:\/\/doi.org\/10.1016\/j.jhep.2014.12.012.","journal-title":"J Hepatol."},{"issue":"36","key":"250_CR8","doi-asserted-by":"publisher","first-page":"6549","DOI":"10.3748\/wjg.v23.i36.6549","volume":"23","author":"S Singh","year":"2017","unstructured":"Singh S, Osna NA, Kharbanda KK. Treatment options for alcoholic and non-alcoholic fatty liver disease: a review. World J Gastroenterol. 2017;23(36):6549\u201370. https:\/\/doi.org\/10.3748\/wjg.v23.i36.6549.","journal-title":"World J Gastroenterol."},{"issue":"1","key":"250_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.15386\/cjmed-539","volume":"89","author":"MA Munteanu","year":"2016","unstructured":"Munteanu MA, Nagy GA, Mircea PA. Current management of NAFLD. Clujul Med. 2016;89(1):19\u201323. https:\/\/doi.org\/10.15386\/cjmed-539.","journal-title":"Clujul Med."},{"issue":"5","key":"250_CR10","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1007\/s12325-019-00898-6","volume":"36","author":"S Francque","year":"2019","unstructured":"Francque S, Vonghia L. Pharmacological treatment for non-alcoholic fatty liver disease. Adv Ther. 2019;36(5):1052\u201374. https:\/\/doi.org\/10.1007\/s12325-019-00898-6.","journal-title":"Adv Ther."},{"issue":"6","key":"250_CR11","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","volume":"64","author":"European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity","year":"2016","unstructured":"European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388\u2013402. https:\/\/doi.org\/10.1016\/j.jhep.2015.11.004.","journal-title":"J Hepatol."},{"issue":"1","key":"250_CR12","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328\u201357. https:\/\/doi.org\/10.1002\/hep.29367.","journal-title":"Hepatology"},{"issue":"Suppl 2","key":"250_CR13","doi-asserted-by":"publisher","first-page":"A108","DOI":"10.1136\/gutjnl-2019-BSGAbstracts.205","volume":"68","author":"Z Younossi","year":"2019","unstructured":"Younossi Z, Ratziu V, Loomba R, Rinella M, Anstee QM, Zaru L, et al. OTU-14 positive results from REGENERATE: a phase 3 international, randomized, placebo-controlled study evaluating obeticholic acid treatment for NASH. Gut. 2019;68(Suppl 2):A108. https:\/\/doi.org\/10.1136\/gutjnl-2019-BSGAbstracts.205.","journal-title":"Gut"},{"issue":"3","key":"250_CR14","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/S1734-1140(11)70576-X","volume":"63","author":"KJ Gundermann","year":"2011","unstructured":"Gundermann KJ, Kuenker A, Kuntz E, Drozdzik M. Activity of essential phospholipids (EPL) from soybean in liver diseases. Pharmacol Rep. 2011;63(3):643\u201359.","journal-title":"Pharmacol Rep."},{"key":"250_CR15","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2147\/CEG.S96362","volume":"9","author":"KJ Gundermann","year":"2016","unstructured":"Gundermann KJ, Gundermann S, Drozdzik M, Mohan Prasad VG. Essential phospholipids in fatty liver: a scientific update. Clin Exp Gastroenterol. 2016;9:105\u201317. https:\/\/doi.org\/10.2147\/CEG.S96362.","journal-title":"Clin Exp Gastroenterol."},{"issue":"3\u20134","key":"250_CR16","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ajg.2015.09.001","volume":"16","author":"AI Dajani","year":"2015","unstructured":"Dajani AI, Abu Hammour AM, Zakaria MA, Al Jaberi MR, Nounou MA, Semrin AI. Essential phospholipids as a supportive adjunct in the management of patients with NAFLD. Arab J Gastroenterol. 2015;16(3\u20134):99\u2013104. https:\/\/doi.org\/10.1016\/j.ajg.2015.09.001.","journal-title":"Arab J Gastroenterol."},{"issue":"62","key":"250_CR17","doi-asserted-by":"publisher","first-page":"58","DOI":"10.22141\/2308-2097.4.62.2016.81089","volume":"4","author":"MY Stepanov","year":"2016","unstructured":"Stepanov MY. The use of essential phospholipids for the treatment of fatty liver (in Russian). Gastroenterology. 2016;4(62):58\u201364. https:\/\/doi.org\/10.22141\/2308-2097.4.62.2016.81089.","journal-title":"Gastroenterology"},{"key":"250_CR18","first-page":"61","volume":"17","author":"Z Gonciarz","year":"1988","unstructured":"Gonciarz Z, Besser P, Lelek E, Gundermann K-J, Johannes KJ. Randomised placebo-controlled double blind trial on \u201cessential\u201d phospholipids in the treatment of fatty liver associated with diabetes. Med Chir Dig. 1988;17:61\u20135.","journal-title":"Med Chir Dig."},{"issue":"4","key":"250_CR19","first-page":"180","volume":"13","author":"JH Li","year":"2000","unstructured":"Li JH, Chen XY, Zhong CF, Min J. A randomized controlled study of essential phospholipids (Essentiale capsules) in the treatment of fatty liver (in Chinese). Infect Dis Inf. 2000;13(4):180\u20131.","journal-title":"Infect Dis Inf."},{"issue":"17","key":"250_CR20","first-page":"1272","volume":"23","author":"C Sun","year":"2008","unstructured":"Sun C, Zheng X, Tan Z, Cui F, Zhang R, Zhang H. Clinical observation on polyene phosphatidyl choline and metformin in the treatment of type 2 diabetes and non-alcoholic fatty liver disease (in Chinese). Clin Focus. 2008;23(17):1272\u20133.","journal-title":"Clin Focus."},{"issue":"31","key":"250_CR21","first-page":"10","volume":"32","author":"L Zhiguo","year":"2013","unstructured":"Zhiguo L. Observation of the efficacy of polyene phosphatidylcholine combined with metformin in the treatment of diabetes with non-alcoholic fatty liver disease (in Chinese). Inner Mongol J Trad Chin Med. 2013;32(31):10\u20131.","journal-title":"Inner Mongol J Trad Chin Med."},{"key":"250_CR22","first-page":"277","volume":"15","author":"D Yin","year":"2000","unstructured":"Yin D, Kong L. Observation for curative effect of Essentiale in treatment of fatty liver caused by diabetes mellitus. Med J Q Ilu. 2000;15:277\u20138.","journal-title":"Med J Q Ilu."},{"issue":"2","key":"250_CR23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.22416\/1382-4376-2016-26-2-24-42","volume":"26","author":"VT Ivashkin","year":"2016","unstructured":"Ivashkin VT, Mayevskaya MV, Pavlov CS, Tikhonov IN, Shirokova YN, Buyeverov AO, et al. Diagnostics and treatment of non-alcoholic fatty liver disease: clinical guidelines of the Russian Scientific Liver Society and the Russian Gastroenterological Association (in Russian). Russian J Gastroenterol Hepatol Coloproctol. 2016;26(2):24\u201342. https:\/\/doi.org\/10.22416\/1382-4376-2016-26-2-24-42.","journal-title":"Russian J Gastroenterol Hepatol Coloproctol"},{"issue":"2","key":"250_CR24","first-page":"22","volume":"138","author":"LB Lazebnik","year":"2017","unstructured":"Lazebnik LB, Radchenko VG, Golovanova EV, Zvenigorodskaya LA, Konev YV, Seliverstov PV, et al. Nonalcoholic fatty liver disease: clinic, diagnostics, treatment (recommendations for therapists, 2nd edition). Eksp Klin Gastroenterol. 2017;138(2):22\u201337.","journal-title":"Eksp Klin Gastroenterol."},{"issue":"183","key":"250_CR25","first-page":"123","volume":"9","author":"AV Nersesov","year":"2017","unstructured":"Nersesov AV, Zhankalova ZM, Raisova AM, Kaibullayeva DA, Dzhumabayeva AE, Novitskaya \u041cS et al. Characterization of outpatients suffering from liver conditions (Chronic viral hepatitis, hepatic steatosis, hepatic disease related todiabetesorobesity) managed under real life conditions and receiving a treatment with Essentiale\u00ae as anadjunctive treatment to standard care (the results of multicenter study REPAIR) (in Russian). Medicine (Almaty). 2017;9(183):123\u201337.","journal-title":"Medicine (Almaty)."},{"key":"250_CR26","first-page":"9","volume":"1","author":"YI Sas","year":"2015","unstructured":"Sas YI, Blinov DV, Zimovina UV. Features of patients treated by essential phospholipids at real life conditions (in Russian). Clin Prospects Gastroenterol Hepatol. 2015;1:9\u201317.","journal-title":"Clin Prospects Gastroenterol Hepatol."},{"key":"250_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2019-000341","author":"IV Maev","year":"2020","unstructured":"Maev IV, Samsonov AA, Palgova LK, Pavlov CS, Vovk EI, Shirokova EN, et al. Effectiveness of phosphatidylcholine in alleviating steatosis in patients with non-alcoholic fatty liver disease and cardiometabolic comorbidities (MANPOWER study). BMJ Open Gastroenterol. 2020. https:\/\/doi.org\/10.1136\/bmjgast-2019-000341.","journal-title":"BMJ Open Gastroenterol"},{"issue":"1","key":"250_CR28","doi-asserted-by":"publisher","first-page":"e000368","DOI":"10.1136\/bmjgast-2019-000368","volume":"7","author":"IV Maev","year":"2020","unstructured":"Maev IV, Samsonov AA, Palgova LK, Pavlov CS, Shirokova EN, Vovk EI, et al. Effectiveness of phosphatidylcholine as adjunctive therapy in improving liver function tests in patients with non-alcoholic fatty liver disease and metabolic comorbidities: real-life observational study from Russia. BMJ Open Gastroenterol. 2020;7(1):e000368. https:\/\/doi.org\/10.1136\/bmjgast-2019-000368.","journal-title":"BMJ Open Gastroenterol."},{"issue":"10","key":"250_CR29","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1136\/gut.2007.146019","volume":"57","author":"SA Harrison","year":"2008","unstructured":"Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 2008;57(10):1441\u20137. https:\/\/doi.org\/10.1136\/gut.2007.146019.","journal-title":"Gut"},{"key":"250_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2019-000307","author":"IV Maev","year":"2019","unstructured":"Maev IV, Samsonov AA, Palgova LK, Pavlov CS, Shirokova E, Starostin KM. Real-world comorbidities and treatment patterns among patients with non-alcoholic fatty liver disease receiving phosphatidylcholine as adjunctive therapy in Russia. BMJ Open Gastroenterol. 2019. https:\/\/doi.org\/10.1136\/bmjgast-2019-000307.","journal-title":"BMJ Open Gastroenterol"},{"issue":"2","key":"250_CR31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4103\/1319-3767.178527","volume":"22","author":"A Dajani","year":"2016","unstructured":"Dajani A, AbuHammour A. Treatment of nonalcoholic fatty liver disease: where do we stand? An overview. Saudi J Gastroenterol. 2016;22(2):91\u2013105. https:\/\/doi.org\/10.4103\/1319-3767.178527.","journal-title":"Saudi J Gastroenterol."},{"key":"250_CR32","doi-asserted-by":"publisher","first-page":"S549","DOI":"10.1016\/S0168-8278(13)61365-3","volume":"58","author":"E Sas","year":"2013","unstructured":"Sas E, Grinevich V, Efimov O, Shcherbina N. Beneficial influence of polyunsaturated phosphatidylcholine enhances functional liver condition and liver structure in patients with nonalcoholic steatohepatitis. Results of prolonged randomized blinded prospective clinical study. J Hepatol. 2013;58:S549.","journal-title":"J Hepatol."},{"key":"250_CR33","first-page":"10","volume":"31","author":"Z Li","year":"2013","unstructured":"Li Z. Efficacy of polyene phosphatidylcholine in combination with metformin for diabetes complicated with non-alcoholic fatty liver disease. Inner Mongol J Trad Chine Med. 2013;31:10\u20131.","journal-title":"Inner Mongol J Trad Chine Med."},{"issue":"4","key":"250_CR34","first-page":"637","volume":"52","author":"H Obayashi","year":"2006","unstructured":"Obayashi H, Fujimoto M, Yoshida M, Ito M, Yamase H. The therapeutic effect of polyenephosphatidylcholine (EPL) on NASH (in Japanese). Liver Bile Pancreas. 2006;52(4):637\u201342.","journal-title":"Liver Bile Pancreas."},{"issue":"11","key":"250_CR35","first-page":"735","volume":"23","author":"L Padma","year":"2013","unstructured":"Padma L, Qayum M, Abhijit T. An observational study of Essentiale-L in the treatment of patients with fatty liver disease. Indian J Clin Pract. 2013;23(11):735\u20139.","journal-title":"Indian J Clin Pract."},{"key":"250_CR36","doi-asserted-by":"crossref","unstructured":"Dajani A, Popovic B. Essential phospholipids in the treatment of non-alcoholic fatty liver disease associated with type 2 diabetes or obesity: a systematic review and network meta-analysis [abstract PO-7-84]. Asian Pacific Association for the Study of the Liver (APASL). 2020.","DOI":"10.12998\/wjcc.v8.i21.5235"},{"issue":"1","key":"250_CR37","doi-asserted-by":"publisher","first-page":"3","DOI":"10.5001\/omj.2014.02","volume":"29","author":"R Al-Abri","year":"2014","unstructured":"Al-Abri R, Al-Balushi A. Patient satisfaction survey as a tool towards quality improvement. Oman Med J. 2014;29(1):3\u20137. https:\/\/doi.org\/10.5001\/omj.2014.02.","journal-title":"Oman Med J."},{"key":"250_CR38","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/PPA.S24752","volume":"6","author":"CD Barbosa","year":"2012","unstructured":"Barbosa CD, Balp MM, Kulich K, Germain N, Rofail D. A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence. Patient Prefer Adherence. 2012;6:39\u201348. https:\/\/doi.org\/10.2147\/PPA.S24752.","journal-title":"Patient Prefer Adherence."},{"issue":"4","key":"250_CR39","doi-asserted-by":"publisher","first-page":"304","DOI":"10.4065\/mcp.2010.0575","volume":"86","author":"MT Brown","year":"2011","unstructured":"Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011;86(4):304\u201314. https:\/\/doi.org\/10.4065\/mcp.2010.0575.","journal-title":"Mayo Clin Proc."},{"issue":"12","key":"250_CR40","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1038\/ajg.2017.371","volume":"112","author":"F Baratta","year":"2017","unstructured":"Baratta F, Pastori D, Polimeni L, Bucci T, Ceci F, Calabrese C, et al. Adherence to Mediterranean diet and non-alcoholic fatty liver disease: effect on insulin resistance. Am J Gastroenterol. 2017;112(12):1832\u20139. https:\/\/doi.org\/10.1038\/ajg.2017.371.","journal-title":"Am J Gastroenterol."},{"key":"250_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.04.030","author":"O Glass","year":"2020","unstructured":"Glass O, Filozof C, Noureddin M, Berner-Hansen M, Schabel E, Omokaro SO, et al. Standardization of diet and exercise in clinical trials of NAFLD-NASH: recommendations from the Liver Forum. J Hepatol. 2020. https:\/\/doi.org\/10.1016\/j.jhep.2020.04.030.","journal-title":"J Hepatol"},{"issue":"1","key":"250_CR42","doi-asserted-by":"publisher","first-page":"12","DOI":"10.4103\/0973-3930.26859","volume":"25","author":"S Poongothai","year":"2005","unstructured":"Poongothai S, Karkuzhali K, Siva Prakash G, Sangaatha T, Saravanan T, Deepa R, et al. Effect of essentiale in diabetic subjects with non-effect of Essentiale in diabetic subjects with non-alcoholic fatty liver. Int J Diabet Dev Ctries. 2005;25(1):12\u20139.","journal-title":"Int J Diabet Dev Ctries."},{"issue":"7\u20138","key":"250_CR43","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.nut.2004.11.019","volume":"21","author":"Y Buang","year":"2005","unstructured":"Buang Y, Wang YM, Cha JY, Nagao K, Yanagita T. Dietary phosphatidylcholine alleviates fatty liver induced by orotic acid. Nutrition. 2005;21(7\u20138):867\u201373. https:\/\/doi.org\/10.1016\/j.nut.2004.11.019.","journal-title":"Nutrition"},{"issue":"3","key":"250_CR44","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/MOL.0b013e3282ffaf96","volume":"19","author":"JS Cohn","year":"2008","unstructured":"Cohn JS, Wat E, Kamili A, Tandy S. Dietary phospholipids, hepatic lipid metabolism and cardiovascular disease. Curr Opin Lipidol. 2008;19(3):257\u201362. https:\/\/doi.org\/10.1097\/MOL.0b013e3282ffaf96.","journal-title":"Curr Opin Lipidol."},{"key":"250_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0129251","author":"T Csak","year":"2015","unstructured":"Csak T, Bala S, Lippai D, Kodys K, Catalano D, Iracheta-Vellve A, et al. MicroRNA-155 deficiency attenuates liver steatosis and fibrosis without reducing inflammation in a mouse model of steatohepatitis. PLoS ONE. 2015. https:\/\/doi.org\/10.1371\/journal.pone.0129251.","journal-title":"PLoS ONE"},{"issue":"9","key":"250_CR46","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.2105\/AJPH.2015.302773","volume":"105","author":"A Fildes","year":"2015","unstructured":"Fildes A, Charlton J, Rudisill C, Littlejohns P, Prevost AT, Gulliford MC. Probability of an obese person attaining normal body weight: cohort study using electronic health records. Am J Public Health. 2015;105(9):e54\u20139. https:\/\/doi.org\/10.2105\/AJPH.2015.302773.","journal-title":"Am J Public Health."},{"key":"250_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph14080922","author":"AWY Leung","year":"2017","unstructured":"Leung AWY, Chan RSM, Sea MMM, Woo J. An overview of factors associated with adherence to lifestyle modification programs for weight management in adults. Int J Environ Res Public Health. 2017. https:\/\/doi.org\/10.3390\/ijerph14080922.","journal-title":"Int J Environ Res Public Health."},{"issue":"5","key":"250_CR48","doi-asserted-by":"publisher","first-page":"597","DOI":"10.4103\/2230-8210.163172","volume":"19","author":"D Sanyal","year":"2015","unstructured":"Sanyal D, Mukherjee P, Raychaudhuri M, Ghosh S, Mukherjee S, Chowdhury S. Profile of liver enzymes in non-alcoholic fatty liver disease in patients with impaired glucose tolerance and newly detected untreated type 2 diabetes. Indian J Endocrinol Metab. 2015;19(5):597\u2013601. https:\/\/doi.org\/10.4103\/2230-8210.163172.","journal-title":"Indian J Endocrinol Metab."},{"issue":"8","key":"250_CR49","doi-asserted-by":"publisher","first-page":"530","DOI":"10.4254\/wjh.v10.i8.530","volume":"10","author":"Q Li","year":"2018","unstructured":"Li Q, Dhyani M, Grajo JR, Sirlin C, Samir AE. Current status of imaging in nonalcoholic fatty liver disease. World J Hepatol. 2018;10(8):530\u201342. https:\/\/doi.org\/10.4254\/wjh.v10.i8.530.","journal-title":"World J Hepatol."}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-021-00250-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-021-00250-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-021-00250-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T04:57:07Z","timestamp":1627707427000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-021-00250-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,15]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["250"],"URL":"https:\/\/doi.org\/10.1007\/s40801-021-00250-x","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,15]]},"assertion":[{"value":"15 April 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Sanofi-Aventis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"K.S. is a Sanofi employee. VTI, MVM, ENS, IVM, AAS, EIS, and LKP have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was a secondary analysis of anonymized patient data from three previously conducted studies, so specific ethics approval was not required. All three studies were approved by the Independent Interdisciplinary Ethics Committee on Ethical Review for Clinical Studies, which is the operating ethics committee in the Russian Federation (MANPOWER: Protocol #13 dated 28 August 2015; LIDER 1: protocol #18 dated 23 November 2012; LIDER 2 protocol #08 dated 17 May 2013).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"This study was a secondary analysis of anonymized patient data from three previously conducted studies; therefore, informed patient consent was not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Qualified researchers may request access to data and related study documents, including the study report, study protocol with any amendments, statistical analysis plan, and dataset specifications. Further details on Sanofi\u2019s data-sharing criteria, eligible studies, and process for requesting access can be found at .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"KS developed the study design and draft protocol, reviewed every version of the manuscript, and enriched the discussion section. VTI, MVM, and IVM contributed to the design of the study and its supervision and discussion. All authors participated in the acquisition, analysis, and interpretation of the data. All authors have also read and approved the final version of the manuscript, except for Liudmila K. Palgova who passed away due to COVID-19 before final submission.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}